Gilles de la Tourette's syndrome - Pipeline Insight, 2024

This “Gilles de la Tourette’s syndrome - Pipeline Insight, 2024,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Gilles de la Tourette’s syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Gilles de la Tourette’s syndrome Understanding

Gilles de la Tourette’s syndrome: Overview

Tourette syndrome (TS) is a disorder that affects the body's brain and nervous system by causing tics - sudden, repetitive movements or sounds that some people make, seemingly without realizing it. A person with Tourette syndrome has mulitple motor tics and at least one vocal tic. Tics are actually more common in teens than you might think. You may know someone who has either a motor tic (sudden, uncontrollable movements like exaggerated blinking of the eyes) or a vocal tic (sounds such as throat clearing, grunting, or humming). Tourette syndrome is a genetic disorder, which means it's the result of a change in genes that's either inherited (passed on from parent to child) or happens during development in the womb. As with other genetic disorders, someone may have a tendency to develop TS. But that doesn't mean the person will definitely get it.

Gilles de la Tourette’s syndrome - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gilles de la Tourette’s syndrome pipeline landscape is provided which includes the disease overview and Gilles de la Tourette’s syndrome treatment guidelines. The assessment part of the report embraces, in depth Gilles de la Tourette’s syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gilles de la Tourette’s syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Gilles de la Tourette’s syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Gilles de la Tourette’s syndrome.

Gilles de la Tourette’s syndrome Emerging Drugs Chapters

This segment of the Gilles de la Tourette’s syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gilles de la Tourette’s syndrome Emerging Drugs

Ecopipam: Emalex BiosciencesEcopipam is an investigational first-in-class drug being evaluated in pediatric patients for the treatment of Tourette Syndrome (TS) and for childhood onset fluency disorder (Stuttering) in adults. Ecopipam selectively blocks the actions of the neurotransmitter dopamine at the D1 receptor. Dopamine is a neurotransmitter in the central nervous system, and its receptors have been classified into two “families” based on their genetic structure: “D1” (including subtypes D1 and D5) and “D2” (including subtypes D2, D3, and D4). D1-receptor super-sensitivity may be a mechanism for the repetitive and compulsive behaviors associated with Tourette Syndrome. The drug is currently in phase II stage of clinical trial evaluation to treat Gilles de la Tourette's syndrome.

THX-110: Therapix BiosciencesTHX-110 is a drug candidate platform for the treatment of symptoms related to Tourette syndrome (TS), as well as Obstructive Sleep Apnea (OSA) and chronic pain. The drug is currently in phase II stage of clinical trial evaluation to treat Gilles de la Tourette's syndrome.

Gilles de la Tourette’s syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Gilles de la Tourette’s syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gilles de la Tourette’s syndrome

There are approx. 6+ key companies which are developing the therapies for Gilles de la Tourette’s syndrome. The companies which have their Gilles de la Tourette’s syndrome drug candidates in the most advanced stage, i.e. phase II include, Emalex Biosciences.

Phases

This report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Gilles de la Tourette’s syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gilles de la Tourette’s syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gilles de la Tourette’s syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gilles de la Tourette’s syndrome drugs.

Gilles de la Tourette’s syndrome Report Insights

• Gilles de la Tourette’s syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Gilles de la Tourette’s syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Gilles de la Tourette’s syndrome drugs?
• How many Gilles de la Tourette’s syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gilles de la Tourette’s syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gilles de la Tourette’s syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gilles de la Tourette’s syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Emalex Biosciences
• Therapix Biosciences
• Catalyst Pharmaceuticals
• KemPharm
• Teva Pharmaceutical
• Neurocrine Biosciences
• Asarina Pharma
• SOM Biotech
• SciSparc

Key Products

• Ecopipam
• THX-110
• CPP 115
• Gilles de la Tourette's syndrome prodrug therapeutic
• Deutetrabenazine
• NBI-98854
• Sepranolone
• SOM3355
• THX 120

This product will be delivered within 2 business days.